The Danish company Novo Nordisk is one of the leading pharmaceutical manufacturers of new diabetes and obesity drugs, though increased competition and other factors saw the company cut its guidance for the second half of 2025 as it seeks new uses for its products (CNBC, Yahoo [GuruFocus], Novo Nordisk). The question will be suspended on 31 December 2025 and the outcome determined using net sales data as reported by Novo Nordisk in its fourth quarter report, expected in February 2026 (Novo Nordisk - Financial Results). For the purposes of this question, "type 2 diabetes and obesity drugs" means GLP-1 agonists, dual GLP-1/GIP receptor agonists, SGLT-2 inhibitors, and other classes of drugs marketed to treat Type 2 diabetes and/or obesity (Mayo Clinic, American Diabetes Association). Sales of drugs that combine a type 2 diabetes or obesity drug with another compound will count. As of the launch of this question, Novo Nordisk was marketing five GLP-1 drugs: Rybelsus, Ozempic, and Victoza, which are marketed for diabetes care, along with Wegovy and Saxenda, which are marketed for obesity care. Sales of the same drug or drugs being sold under a different name will count. For the second half of 2024, Novo Nordisk reported selling a total of 117,315 million Danish Kroner (DKK), or 117.315 billion DKK (Novo Nordisk - Financial Results, click "Download financial workbook (xlsx)" under Q4 for 2024 and see "Sales - Q"). Annual (2019-2024) and quarterly (Q1 2023-Q2 2025) net sales data by drug may be viewed by downloading this xlsx file (Novo Nordisk Annual GLP-1 Net Sales 2019-2024 & Quarterly 2023-25YTD 9 September_2025.xlsx).

Confused? Check our FAQ or ask us for help. To learn more about Good Judgment and Superforecasting, click here.

To learn more about how you can become a Superforecaster, see here. For other posts from our Insights blog, click here.